Heartland Advisors’s Heron Therapeutics HRTX Stock Holding History

Heartland Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-200,000	Closed	-$4.23M	–	235
2020 Q4	$4.23M	Sell	200,000 -175,000	-47%	-$3.04M	0.3%	133
2020 Q3	$5.56M	Hold	375,000	–	–	0.48%	90
2020 Q2	$5.52M	Hold	375,000	–	–	0.49%	91
2020 Q1	$4.4M	Buy	375,000 +50,000	+15%	+$940K	0.47%	102
2019 Q4	$7.64M	Sell	325,000 -75,000	-19%	-$1.66M	0.56%	78
2019 Q3	$7.4M	Hold	400,000	–	–	0.56%	77
2019 Q2	$7.44M	Buy	+400,000	New	+$7.99M	0.55%	83

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Heartland Advisors's HRTX Position: Q1 2021 in Review

Heartland Advisors sold out of Heron Therapeutics (HRTX) in Q1 2021, closing a stake of 200,000 shares — an estimated $4.23M sold.

Heartland Advisors first reported a position in HRTX in Q2 2019 and held it in 7 quarters. The position peaked at $7.64M in Q4 2019. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2021.

Heartland Advisors reported no remaining Heron Therapeutics position as of Q1 2021 after selling out during the quarter.
Heartland Advisors sold 200,000 Heron Therapeutics shares in Q1 2021, an estimated $4.23M.
Heartland Advisors first reported a position in Heron Therapeutics in Q2 2019 and held it in 7 quarters.
Heartland Advisors's Heron Therapeutics position peaked at $7.64M in Q4 2019.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2021.

Based on Heartland Advisors's 13F filing for Q1 2021, filed 12 May 2021.